loading page

Irinotecan Plus Doxorubicin Hydrochloride Liposome for Relapsed or Refractory Wilms Tumor
  • +10
  • Lian Zhang,
  • Juan Wang,
  • Lanying Guo,
  • Yi Que,
  • Feifei Sun,
  • Jia Zhu,
  • Su-Ying Lu,
  • Junting Huang,
  • Wu Liuhong,
  • Ruiqing Cai,
  • Zijun Zhen,
  • Yizhuo Zhang,
  • Xiaofei Sun
Lian Zhang
Sun Yat-sen University Cancer Center
Author Profile
Juan Wang
Sun Yet-Sen University Cancer Center
Author Profile
Lanying Guo
Fifth Affiliated Hospital of Guangzhou Medical College
Author Profile
Yi Que
Sun Yat-sen University Cancer Center
Author Profile
Feifei Sun
Sun Yat-sen University Cancer Center
Author Profile
Jia Zhu
Sun Yet-Sen University Cancer Center
Author Profile
Su-Ying Lu
Sun Yat-sen University Cancer Center
Author Profile
Junting Huang
Sun Yet-Sen University Cancer Center
Author Profile
Wu Liuhong
Sun Yat-sen University Cancer Center
Author Profile
Ruiqing Cai
Sun Yet-Sen University Cancer Center
Author Profile
Zijun Zhen
Sun Yat-sen University Cancer Center
Author Profile
Yizhuo Zhang
Sun Yat-sen University Cancer Center
Author Profile
Xiaofei Sun
Sun Yet-Sen University
Author Profile

Abstract

Purpose: The prognosis of the relapsed or refractory Wilms tumor (R/R WT) was dismal and new salvage chemotherapy was needed. This study aimed to evaluate the efficacy of the combination of irinotecan and doxorubicin hydrochloride liposome regimen (AI) for R/R WT. Methods: The present study enrolled the R/R WT who were treated with AI regimen at Sun Yat-Sen University Cancer Center from July 2018 to September 2020. The response was defined as the best observed response after the last two cycle and toxicity was evaluated. Result: Total of 16 patients with median age of 4.2 years (0.5 to 11 years) were enrolled, including 14 patients with relapsed disease and 2 patients with refractory disease. These patients received 1 to 8 courses (median 3 courses).14 patients were assessable for response: 2 complete response (CR), 5 partial response (PR), 2 stable disease (SD), 5 progression disease (PD). The objective response rate was 50% (2 CR, 5 PR) and the disease control rate was 64% (2 CR, 5 PR, and 2 SD). The median progression-free survival was 3.5 months (range 0.5-12 months), and the median survival duration was 8 months (range 1-28 months). Sixteen patients were assessable for toxicity, with most common grade 3 or 4 adverse events were alopecia (62%), leucopenia (40%), abdominal pain (38%), etc. No fatal adverse events have been observed. Conclusion: The AI regimen has positive efficacy with tolerated toxicity, it may provide an alternative option for the treatment of R/R WT.